SRPT Sarepta Therapeutics Potential Buyout Soon

If you haven`t bought SRPT here:

Then you need to know that there is a Massive catalyst coming!
Sarepta Therapeutics is going to announce Duchenne muscular dystrophy Phase 3 data for its SRP-9001-301 - (EMBARK) by mid November.

This week institutions bought calls worth more than $10Mil that SRPT Sarepta Therapeutics will trade above $135 by November 17.
Some even bought the $210 strike price!

They also have a big partnership with the giant Roche Holding AG (RHHBY).

I think SRPT Sarepta Therapeutics is well positioned for a potential takeover soon!

Looking forward to read your opinion about it.